Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case-control study'

Ann Rheum Dis. 2023 Aug;82(8):e182. doi: 10.1136/annrheumdis-2020-218836. Epub 2020 Sep 21.
No abstract available

Keywords: anti-inflammatory agents; biological therapy; cytokines; immune system diseases; inflammation; non-steroidal.

Publication types

  • Letter

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Case-Control Studies
  • Humans
  • Receptors, Interleukin-6
  • Treatment Outcome

Substances

  • tocilizumab
  • Receptors, Interleukin-6